162 related articles for article (PubMed ID: 21159366)
21. Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Van Kooten M; Traine G; Cinat G; Cazap E; Comba AZ; Vicente H; Sena S; Nievas OR; Orlando M
Br J Cancer; 1999 Nov; 81(5):846-9. PubMed ID: 10555756
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction.
Sandler AB; Kindler HL; Einhorn LH; Mitchell E; Masters G; Kraut M; Nicol S; Raghavan D
Ann Oncol; 2000 Sep; 11(9):1161-4. PubMed ID: 11061612
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study.
Samlowski WE; Gundacker H; Kuebler JP; Giguere JK; Mills GM; Schuller DE; Ensley JF
Invest New Drugs; 2001; 19(4):311-5. PubMed ID: 11561690
[TBL] [Abstract][Full Text] [Related]
26. [Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)].
Fukuoka M; Negoro S; Kudo S; Furuse K; Nishikawa H; Takada Y; Kamei T; Niitani H; Taguchi T
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1825-32. PubMed ID: 8937493
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
Yokoyama T; Yoshida H; Makino H; Maruyama H; Suzuki S; Matsutani T; Matsushita A; Hirakata A; Sasajima K; Uchida E
J Nippon Med Sch; 2012; 79(3):204-12. PubMed ID: 22791122
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix.
Burnett AF; Roman LD; Garcia AA; Muderspach LI; Brader KR; Morrow CP
Gynecol Oncol; 2000 Jan; 76(1):63-6. PubMed ID: 10620443
[TBL] [Abstract][Full Text] [Related]
29. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.
Brown J; Smith JA; Ramondetta LM; Sood AK; Ramirez PT; Coleman RL; Levenback CF; Munsell MF; Jung M; Wolf JK
Cancer; 2010 Nov; 116(21):4973-9. PubMed ID: 20665499
[TBL] [Abstract][Full Text] [Related]
30. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.
Watanabe Y; Koike E; Nakai H; Etoh T; Hoshiai H
Int J Clin Oncol; 2008 Aug; 13(4):345-8. PubMed ID: 18704636
[TBL] [Abstract][Full Text] [Related]
32. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR
J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509
[TBL] [Abstract][Full Text] [Related]
33. Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
Yoshino K; Hiramatsu K; Enomoto T; Fujita M; Ueda Y; Kimura T; Kobayashi E; Kiyohara Y; Tsutsui T; Kimura T
Anticancer Res; 2012 Sep; 32(9):4029-33. PubMed ID: 22993355
[TBL] [Abstract][Full Text] [Related]
34. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
[TBL] [Abstract][Full Text] [Related]
35. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy.
Zhang L; Zhang Y; Huang PY; Xu F; Peng PJ; Guan ZZ
Cancer Chemother Pharmacol; 2008 Jan; 61(1):33-8. PubMed ID: 17909810
[TBL] [Abstract][Full Text] [Related]
36. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Kindler HL; Aklilu M; Nattam S; Vokes EE
Am J Clin Oncol; 2008 Dec; 31(6):553-6. PubMed ID: 19060586
[TBL] [Abstract][Full Text] [Related]
37. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
Boukovinas I; Androulakis N; Vamvakas L; Papakotoulas P; Ziras N; Polyzos A; Kalykaki A; Kotsakis A; Xenidis N; Gioulmbasanis I; Mavroudis D; Georgoulias V
Ann Oncol; 2006 Nov; 17(11):1687-92. PubMed ID: 16968872
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study.
Lilenbaum R; Cano R; Schwartz M; Siegel L; Lutzky J; Lewis M; Krill E; Barreras L; Davila E
Cancer; 2000 Feb; 88(3):557-62. PubMed ID: 10649247
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
Schilder RJ; Blessing JA; Pearl ML; Rose PG
Invest New Drugs; 2004 Aug; 22(3):343-9. PubMed ID: 15122083
[TBL] [Abstract][Full Text] [Related]
40. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
